U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Mucosal Melanoma

MedGen UID:
1730067
•Concept ID:
C5418899
•
Neoplastic Process

Definition

The reemergence of a mucosal melanoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Mucosal Melanoma

Professional guidelines

PubMed

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, Hieken TJ, Izar B, Johnson DB, Kulkarni RP, Luke JJ, Mitchell TC, Mooradian MJ, Rubin KM, Salama AK, Shirai K, Taube JM, Tawbi HA, Tolley JK, Valdueza C, Weiss SA, Wong MK, Sullivan RJ
J Immunother Cancer 2023 Oct;11(10) doi: 10.1136/jitc-2023-006947. PMID: 37852736Free PMC Article
Management of Head and Neck Mucosal Melanoma.
Nenclares P, Harrington KJ
Oral Maxillofac Surg Clin North Am 2022 May;34(2):299-314. Epub 2022 Apr 8 doi: 10.1016/j.coms.2021.11.008. PMID: 35400572
Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment.
Wohlmuth C, Wohlmuth-Wieser I
Am J Clin Dermatol 2021 Sep;22(5):639-651. Epub 2021 Jun 14 doi: 10.1007/s40257-021-00614-7. PMID: 34125416Free PMC Article

Recent clinical studies

Etiology

Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M, Nakajima H, Hosono A, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakao T, Funasaka C, Kondoh C, Harano K, Matsubara N, Naito Y, Akimoto T, Mukohara T
Melanoma Res 2023 Dec 1;33(6):547-552. Epub 2023 Sep 4 doi: 10.1097/CMR.0000000000000924. PMID: 37696254
Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.
Zhang X, Jin F, Jiang S, Cao J, Meng Y, Xu Y, ChunmengWang, Chen Y, Yang H, Kong Y, Liu X, Luo Z
Invest New Drugs 2022 Apr;40(2):453-460. Epub 2021 Nov 3 doi: 10.1007/s10637-021-01172-9. PMID: 34731354

Diagnosis

Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M, Nakajima H, Hosono A, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakao T, Funasaka C, Kondoh C, Harano K, Matsubara N, Naito Y, Akimoto T, Mukohara T
Melanoma Res 2023 Dec 1;33(6):547-552. Epub 2023 Sep 4 doi: 10.1097/CMR.0000000000000924. PMID: 37696254
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Satish T, Khan S, Levin M, Carvajal R, Yoon AJ
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2020-001219. PMID: 34716205Free PMC Article

Therapy

Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M, Nakajima H, Hosono A, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakao T, Funasaka C, Kondoh C, Harano K, Matsubara N, Naito Y, Akimoto T, Mukohara T
Melanoma Res 2023 Dec 1;33(6):547-552. Epub 2023 Sep 4 doi: 10.1097/CMR.0000000000000924. PMID: 37696254
Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.
Zhang X, Jin F, Jiang S, Cao J, Meng Y, Xu Y, ChunmengWang, Chen Y, Yang H, Kong Y, Liu X, Luo Z
Invest New Drugs 2022 Apr;40(2):453-460. Epub 2021 Nov 3 doi: 10.1007/s10637-021-01172-9. PMID: 34731354
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Satish T, Khan S, Levin M, Carvajal R, Yoon AJ
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2020-001219. PMID: 34716205Free PMC Article
Treatment of locally recurrent mucosal melanoma with topical imiquimod.
Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, Bogatch K, Chapman PB, Wolchok JD, Schwartz GK, Carvajal RD
J Clin Oncol 2011 Nov 20;29(33):e809-11. Epub 2011 Oct 17 doi: 10.1200/JCO.2011.36.8829. PMID: 22010009

Prognosis

Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M, Nakajima H, Hosono A, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakao T, Funasaka C, Kondoh C, Harano K, Matsubara N, Naito Y, Akimoto T, Mukohara T
Melanoma Res 2023 Dec 1;33(6):547-552. Epub 2023 Sep 4 doi: 10.1097/CMR.0000000000000924. PMID: 37696254

Clinical prediction guides

Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.
Zhang X, Jin F, Jiang S, Cao J, Meng Y, Xu Y, ChunmengWang, Chen Y, Yang H, Kong Y, Liu X, Luo Z
Invest New Drugs 2022 Apr;40(2):453-460. Epub 2021 Nov 3 doi: 10.1007/s10637-021-01172-9. PMID: 34731354
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Satish T, Khan S, Levin M, Carvajal R, Yoon AJ
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2020-001219. PMID: 34716205Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...